20,99 €
0,37 %
L&S, 20. Januar, 19:35 Uhr
ISIN
US28414H1032
Symbol
ELAN
Berichte

Elanco Animal Health, Inc. Aktie News

Neutral
Seeking Alpha
7 Tage alt
Elanco Animal Health Incorporated (ELAN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Positiv
Seeking Alpha
11 Tage alt
Elanco Animal Health earns a buy rating, driven by robust product innovation, commercial execution, and a credible deleveraging plan. ELAN's 'Big 6' innovation portfolio is set to contribute ~$1.1 billion in 2026 revenue, supporting margin expansion and portfolio renewal. Credelio Quattro and Zenrelia demonstrate ELAN's ability to capture share from incumbents, with rapid adoption and strong se...
Neutral
PRNewsWire
14 Tage alt
INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.
Neutral
PRNewsWire
20 Tage alt
Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age against canine atopic dermatitis and allergic dermatitis for 6 to 8 weeks of treatment, as needed USDA approval of Befrena reinforces Elanco's commitment to going beyond to deliver differentiated,...
Neutral
PRNewsWire
etwa ein Monat alt
Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's Conditional Approval of Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first for companion animals against New World screwworm Action follows previous Emergency...
Neutral
Seeking Alpha
etwa ein Monat alt
Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript
Positiv
Investors Business Daily
etwa ein Monat alt
Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.
Neutral
PRNewsWire
etwa ein Monat alt
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen